Haleos Labs

Haleos Labs' material subsidiary Mahi Drugs Private Limited completed a US Food and Drug Administration inspection at its active pharmaceutical ingredient facility in Parawada, Andhra Pradesh, between 15 and 18 September 2026. The inspection closed with zero Form 483 observations, matching the outcome of the January 2025 inspection at the same site. Mahi Drugs was 60% owned by Haleos Labs and reported revenue of Rs60.20 crore with a profit of Rs1.22 crore in the year to March 2026, after a loss in the prior year. The group's Kazipally active ingredient facility received a Voluntary Action Indicated classification in July 2025 and cleared an ANVISA inspection in September 2025. Haleos Labs reported consolidated revenue of Rs333.79 crore in the year to March 2026 and operated plants at Kazipally and Jeedimetla with research at Sanathnagar.

Powered by Tijori

** SMS Lifesciences India SMSL.NS soars 17% to 1,342.2 rupees; set to snap four sessions of losses

** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in Telangana gets establishment inspection report from U.S. FDA with "voluntary action indicated" (VAI)

** A VAI classification implies facility won't face any regulatory action

** SMSL, which jumped 17% prior to the news, held gains after company disclosure

** Stock set for best day since August 12, 2024

** SMSL moved above its 50-day, 100-day, 200-day simple moving avgs

** Stock sees most active session since August 12, 2024, with more than 82,000 shares traded - 70x the 30-day moving avg

** YTD, SMSL gains 13.4%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))